{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:22:33Z","timestamp":1791030153417,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a substudy of the HORIZON pivotal fracture trial, in which yearly intravenous zoledronic acid 5 mg was found to significantly reduce risk of various fracture types in patients with postmenopausal osteoporosis, 152 patients underwent bone biopsy. Zoledronic acid reduced bone turnover by 63% and preserved bone structure and volume, with evidence of ongoing bone remodeling in 99% of biopsies obtained.<\/jats:p>\n                  <jats:p>Introduction: In the HORIZON pivotal fracture trial (PFT), enrolling 7736 women with postmenopausal osteoporosis, three annual intravenous infusions of the bisphosphonate zoledronic acid (5 mg) significantly reduced morphometric vertebral, clinical vertebral, hip, and nonvertebral fractures by 70%, 77%, 41%, and 25%, respectively. Whereas 79% of patients received zoledronic acid\/placebo only (stratum I, n = 6113), 21% received concomitant treatment with other antiresorptive drugs, excluding other bisphosphonates, PTH, and strontium (stratum II, n = 1652).<\/jats:p>\n                  <jats:p>Materials and Methods: To determine effects on bone remodeling and bone architecture, iliac crest bone biopsies were obtained in 152 patients on active treatment or placebo at 3 yr after double tetracycline labeling. In five patients, only qualitative histology was performed, leaving 147 biopsy cores (79 on active treatment and 68 on placebo) for \u03bdCT analysis and histomorphometry.<\/jats:p>\n                  <jats:p>Results: Analysis of bone structure by \u03bdCT revealed higher trabecular bone volume (BV\/TV) in the zoledronic acid group (median, 16.6% versus 12.8%; p = 0.020). In addition, patients treated with zoledronic acid exhibited higher trabecular numbers (p = 0.008), decreased trabecular separation (p = 0.011), and a trend toward improvement in connectivity density (p = 0.062), all indicating better preservation of trabecular structure after treatment with zoledronic acid. Qualitative analysis revealed presence of tetracycline label in 81 of 82 biopsies from patients on zoledronic acid and all 70 biopsies from placebo patients, indicative of continued bone remodeling. No bone pathology was observed. Zoledronic acid induced a 63% median (71% mean) reduction of the activation frequency (Ac.f; p &amp;lt; 0.0001) and reduced mineralizing surface (MS\/BS; p &amp;lt; 0.0001) and volume referent bone formation rate (BFR\/BV) versus placebo, indicating reduced bone turnover. Mineral appositional rate was higher in the zoledronic acid group (p = 0.0002), suggesting improved osteoblast function compared with placebo. Mineralization lag time was similar in the two groups, whereas osteoid volume (OV\/BV; p &amp;lt; 0.0001) and osteoid thickness (O. Th; p = 0.0094) were lower in zoledronic acid-treated patients, indicating normal osteoid formation and mineralization of newly formed bone. Concomitant administration of other antiresorptive osteoporosis therapies (e.g., raloxifene, tamoxifen, tibolone, ipriflavone) did not significantly alter the tissue level response to zoledronic acid.<\/jats:p>\n                  <jats:p>Conclusions: Annual dosing for 3 yr with zoledronic acid 5 mg intravenously resulted in a median 63% (mean, 71%) reduction of bone turnover and preservation of bone structure and mass without any signs of adynamic bone. Concomitant treatment with other osteoporosis therapies did not significantly affect the bone response to zoledronic acid.<\/jats:p>","DOI":"10.1359\/jbmr.070906","type":"journal-article","created":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T09:05:32Z","timestamp":1190624732000},"page":"6-16","source":"Crossref","is-referenced-by-count":181,"title":["Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure"],"prefix":"10.1093","volume":"23","author":[{"given":"Robert R","family":"Recker","sequence":"first","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D","family":"Delmas","sequence":"additional","affiliation":[{"name":"INSERM Research Unit 831 and University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Halse","sequence":"additional","affiliation":[{"name":"Betanien Medical Center, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R","family":"Reid","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[{"name":"Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A","family":"Garc\u00eda-Hernandez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Monterrey, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[{"name":"Sniadecki Hospital, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Hospital ABC, Sante Fe, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Hu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mesenbrink","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Hartl","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juerg","family":"Gasser","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319442722500_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jbmr.5650050402","article-title":"Cancellous bone remodeling in type I (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels","volume":"5","author":"Eriksen","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01880415","article-title":"Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal women","volume":"1","author":"Arlot","year":"1990","journal-title":"Osteoporos Int"},{"key":"2024020319442722500_bib3","first-page":"574","article-title":"The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate","volume":"78","author":"Jowsey","year":"1971","journal-title":"J Lab Clin Med"},{"key":"2024020319442722500_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2024020319442722500_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024020319442722500_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"2024020319442722500_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1588-3","article-title":"Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid","volume":"15","author":"Glatt","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024020319442722500_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"2024020319442722500_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2818.1997.1340694.x","article-title":"A new method for the model-independent assessment of thickness in three-dimensional images","volume":"185","author":"Hildebrand","year":"1997","journal-title":"J Microscopy (Oxf)"},{"key":"2024020319442722500_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02347054","article-title":"3D micro-computed tomography of trabecular and cortical bone architecture with application to a rat model of immobilisation osteoporosis","volume":"38","author":"Laib","year":"2000","journal-title":"Med Biol Eng Comput"},{"key":"2024020319442722500_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S8756-3282(97)00007-0","article-title":"Three-dimensional methods for quantification of cancellous bone architecture","volume":"20","author":"Odgaard","year":"1997","journal-title":"Bone"},{"key":"2024020319442722500_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","article-title":"Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography","volume":"73","author":"Dufresne","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2024020319442722500_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079904X20259","article-title":"Trabecular bone microarchitecture after alendronate treatment of osteoporotic women","volume":"21","author":"Recker","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2024020319442722500_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.1997.12.1.6","article-title":"Bone microdamage and skeletal fragility in osteoporotic and stress fractures","volume":"12","author":"Burr","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib16","volume-title":"Current Concepts in Bone Fragility","author":"Frost","year":"1985"},{"key":"2024020319442722500_bib17","first-page":"27","article-title":"Presence of microscopic cracks in vivo in bone","volume":"8","author":"Frost","year":"1960","journal-title":"Henry Ford Med Bull"},{"key":"2024020319442722500_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0142-1123(00)00053-0","article-title":"Fatigue and repair in bone","volume":"22","author":"Schaffler","year":"2000","journal-title":"Int J Fatigue"},{"key":"2024020319442722500_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","article-title":"The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime","volume":"12","author":"Steiniche","year":"1991","journal-title":"Bone"},{"key":"2024020319442722500_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/edrv-7-4-379","article-title":"Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease","volume":"7","author":"Eriksen","year":"1986","journal-title":"Endocr Rev"},{"key":"2024020319442722500_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"2024020319442722500_bib22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment\u2014The Fracture Intervention Trial long-term extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"Suppl","key":"2024020319442722500_bib23","first-page":"S16","article-title":"Microcrack frequency and bone turnover in osteoporotic women on long term bisphosphonates: A bone biopsy study","volume":"21","author":"Chapurlat","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","article-title":"Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis","volume":"41","author":"Stepan","year":"2007","journal-title":"Bone"},{"key":"2024020319442722500_bib25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2024020319442722500_bib27","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1359\/jbmr.060701","article-title":"Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate","volume":"21","author":"Durchschlag","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","article-title":"The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover","volume":"37","author":"Borah","year":"2005","journal-title":"Bone"},{"key":"2024020319442722500_bib29","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.biomaterials.2005.04.059","article-title":"Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells","volume":"26","author":"von Knoch","year":"2005","journal-title":"Biomaterials"},{"key":"2024020319442722500_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro","volume":"34","author":"Pan","year":"2004","journal-title":"Bone"},{"key":"2024020319442722500_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319442722500_bib32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"2024020319442722500_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S8756-3282(01)00424-0","article-title":"How many patients are needed? Variation and design considerations in bone histomorphometry","volume":"28","author":"Hauge","year":"2001","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.070906","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/1\/6\/56571563\/5650230103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/1\/6\/56571563\/5650230103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:49:48Z","timestamp":1710326988000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/1\/6-16\/7599592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.070906","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1097700.553810","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,1,1]]},"published":{"date-parts":[[2008,1,1]]}}}